Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany

Jörg Ruof, Dietrich Knoerzer, Anja-Alexandra Dünne, Charalabos-Markos Dintsios, Thomas Staab and Friedrich Wilhelm Schwartz

Health Policy, 2014, vol. 118, issue 2, 242-254

Abstract: In Germany, a mandatory early benefit assessment (EBA) by the Federal Joint Committee (G-BA) is required for reimbursement of new marketing-authorised medicines. Additional benefit is based on patient-relevant endpoints in mortality, morbidity and health-related quality of life (HRQoL). We aimed to compare endpoints and related benefit categories used in marketing authorisation to those considered by G-BA in the field of oncology.

Keywords: (Early) benefit assessment; Patient-relevant endpoints; Mortality; Morbidity; Health-related quality of life; Oncology (search for similar items in EconPapers)
Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (6)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S016885101400205X
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:118:y:2014:i:2:p:242-254

DOI: 10.1016/j.healthpol.2014.08.004

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().